louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05535894: Endoscopic Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
Official title: Endoscopic Ultrasound-guided Radiofrequency Ablation of Celiac Ganglion for Pain Management and Improvement of Quality of Life in Patients With Unresectable Pancreatic Cancer
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pancreatic Cancer
Lead sponsor: West Virginia University
Sponsor class: OTHER
First posted: 2022-09-10
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with advanced pancreatic cancer who are deemed as non-surgical candidates

Brief summary: This study aims to evaluate the EUS-RFA in terms of efficacy for pain management and improvement in quality-of-life parameters for patients with advanced inoperable pancreatic cancer. The primary objectives of this study are to 1) evaluate the utility of EUS-RFA for pain control and improvement in quality-of-life parameters for patients with advanced pancreatic cancer; 2) to measure the reduction of analgesic medications' requirements in patients affected by inoperable pancreatic cancer.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of pancreatic cancer based on clinical, radiological, or pathological assessment;
* Referred for abdominal and/or back pain due to pancreatic cancer;
* No prior history of RFA;
* Cancer pain unresponsive to the WHO 3-step analgesic ladder;
* Willingness to consent to participate in the study.

Exclusion Criteria:

* Patients who are not willing to give informed consent or agree to participate in the study
* Surgically resectable pancreatic cancer;
* Abdominal pain with etiology other than pancreatic malignancy;
* Evidence of concurrent infection;
* Patients with irreversible coagulopathy international normalized ratio \>1.5 or platelet count \<50,000/mm3),
* Patients with a preliminary diagnosis of adenocarcinoma are not possible established with intraprocedural at EUS-guided FNA.

Primary outcomes:
measure: Pain severity-BPI
timeFrame: From Baseline up to 3 Months
measure: Pain severity-VAS
timeFrame: From Baseline up to 3 Months
measure: Pain severity-NRS
timeFrame: From Baseline up to 3 Months
measure: Quality of Life (EORTC PAN26)
timeFrame: From Baseline up to 3 Months
measure: Quality of Life (EORTC C30)
timeFrame: From Baseline up to 3 Months
measure: Quality of Life (NFHSI)
timeFrame: From Baseline up to 3 Months
measure: Concomitant Analgesic/Narcotic Use
timeFrame: From Baseline up to 3 Months
Secondary outcomes:
Other outcomes:
Locations:
city: Morgantown
country: United States
facility: Shailendra Singh
state: West Virginia
Study officials:
affiliation: West Virginia University
name: Shailendra Singh, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03208894: Role of Salbutamol and Furosemide in TTN
Official title: Role of Salbutamol and Furosemide in Transient Tachypnea of Newborn
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Transient Tachypnea of the Newborn
Lead sponsor: Armed Forces Hospital, Pakistan
Sponsor class: OTHER
First posted: 2017-07-06
Enrollment: 100
Sex: ALL
Minimum age (years): 1
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: to see the effects of slabutamol and IV furosemide in the treatment of transient tachypnea of newborn


Eligibility criteria: Inclusion Criteria:

* all newborn babies with clinically diagnosed TTN

Exclusion Criteria:

* babies less than 34 weeks babies with congenital malformations and CHD

Primary outcomes:
measure: duration of oxygen requiremment in neonates having TTN.
timeFrame: upto 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Department of Pediatrics
state: Punjab
city: Rawalpindi
country: Pakistan
facility: Military Hospital
state: Punjab
Study officials:
References:
Clinical trial NCT00980694: Bioavailability of Ubiquinol in Huntington Disease
Official title: Bioavailability of Ubiquinol in Huntington Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Huntington Disease
Keywords: ubiquinol
coenzyme Q10
Huntington disease
Lead sponsor: University of Rochester
Sponsor class: OTHER
Collaborators: name: Kaneka Corporation
First posted: 2009-09-21
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP

Brief summary: The death of brain cells in Huntington Disease (HD) is thought to be associated with a lack of normal cell energy and harmful brain substances called free radicals. Coenzyme Q10 (CoQ) is a marketed nutritional supplement that may prove useful in HD because it increases cell energy and combats free radicals.

Most studies of CoQ have looked at only one formulation of CoQ ("ubiquinone") in HD. The purpose of the study is to find out if people that switch from the common formulation of CoQ ("ubiquinone") to a different formulation ("ubiquinol") have higher levels of CoQ in their blood after taking the same dose. The investigators also want to find out if this different formulation is tolerable for individuals with HD.


Eligibility criteria: Inclusion Criteria:

* Have manifest Huntington disease
* Be 18 years of age or older
* Be taking an oxidized formulation of CoQ for at least 30 days prior to the baseline visit
* Be on a steady dose of all concomitant medications for at least 30 days prior to the baseline visit

Exclusion Criteria:

* Have a history of intolerability of sensitivity to CoQ
* Have an unstable medical or psychiatric illness
* Be pregnant or breastfeeding; women of childbearing age must use reliable contraception

Primary outcomes:
measure: serum coenzyme Q10 levels
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: University of Rochester
state: New York
Study officials:
affiliation: University of Rochester
name: Karl Kieburtz, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03492294: The Role of Music Stimulation in Disorders of Consciousness State: an fMRI Study
Official title: The Role of Music Stimulation in Disorders of Consciousness State: an fMRI Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Vegetative State
Minimally Conscious State
Keywords: disorders of consciousness
music stimulation
functional magnetic resonance imaging
Lead sponsor: Hangzhou Normal University
Sponsor class: OTHER
First posted: 2018-04-10
Enrollment: 11
Sex: ALL
Minimum age (years): 21
Maximum age (years): 61
Standard ages: ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: patients with disorders of consciousness

Brief summary: The aim of the present study was to evaluated the neural effect of music on the cerebral activation in unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS) by using functional magnetic resonance imaging (fMRI).

Detailed description: Background: Sensory stimulations were used widely to evaluate the preserved cerebral functions for these patients with disorders of consciousness. Among these, the most alerting or common stimuli are probably familiar voice and music.

Objective: The aim of the present study was to evaluated the neural effect of music on the cerebral activation in unresponsive wakefulness syndrome (UWS) and minimally conscious state (MCS) by using functional magnetic resonance imaging (fMRI).

Methods: Eleven severely brain-damaged patients (6 UWS and 5 MCS) were assessed by functional magnetic resonance imaging while they were exposed under the condition of their personal music. To examine the prognostic value of these patients, longitudinal behavioral assessments were repeatedly conducted by means of the CRS-R after fMRI acquisition.

Eligibility criteria: Inclusion Criteria:

* age ≥ 18 years old;
* no administration of neuromuscular blockers or sedation within the 24 hours of enrolment;
* brain damage with eye opening (indicating wakefulness and rest cycles)

Exclusion Criteria:

* Coma;
* neurodegenerative disease;
* psychiatric or neurologic illness;
* with intracranial metal or other body metal.

Primary outcomes:
measure: Coma Recovery Scale-Revised
timeFrame: one to two years
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: International Vegetative State and Consciousness Science Institute, Hangzhou Normal University
state: Zhejiang
Study officials:
affiliation: International Vegetative State and Consciousness Science Institute, Hangzhou Normal University
name: Haibo Di, Pro
role: STUDY_CHAIR
References:
citation: Owen AM, Coleman MR. Detecting awareness in the vegetative state. Ann N Y Acad Sci. 2008;1129:130-8. doi: 10.1196/annals.1417.018.
Clinical trial NCT04621994: Cesarean Wound Closure: Dermabond Versus Steri Strips
Official title: Cesarean Wound Closure: Dermabond Versus Steri Strips
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Scar
Lead sponsor: University of Tennessee
Sponsor class: OTHER
First posted: 2020-11-09
Enrollment: 133
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine overall patient satisfaction with their cesarean section scar with application of Steri-strips vs. Dermabond following subcuticular skin closure of pfannenstiel incision


Eligibility criteria: Inclusion Criteria:

* Women age 18-45 who are undergoing planned or unscheduled cesarean section at Regional One Health
* Gestational age \> 24 weeks
* Planned Pfannenstiel incision
* Willing to consent to the study

Exclusion Criteria:

* Emergency or urgent cesarean section
* Vertical skin incision
* Intrapartum intraamniotic infection
* Diabetes
* Unwilling to consent to the study

Primary outcomes:
measure: Patient and Observer Scar Assessment Scale Surveys (POSAS)
timeFrame: at 1 weeks postpartum
measure: Patient and Observer Scar Assessment Scale Surveys
timeFrame: at 6 weeks postpartum
Secondary outcomes:
measure: Number of patients with wound infection
timeFrame: through 6 weeks postpartum
measure: Number of patients with wound separation or dehiscence
timeFrame: through 6 weeks postpartum
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03529994: Work of Breathing and Oxygen Saturation in Infants Receiving High Flow Nasal Cannula (HFNC)
Official title: Work of Breathing and Oxygen Saturation Stability in Infants With Respiratory Insufficiency While Receiving Various Flow Rates of High Flow Nasal Cannula
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: High Flow Nasal Cannula
Lead sponsor: Christiana Care Health Services
Sponsor class: OTHER
Collaborators: name: Alfred I. duPont Hospital for Children
First posted: 2018-05-21
Enrollment: 30
Sex: ALL
Maximum age (years): 6
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Convenience sample of infants on HFNC admitted to our NICU who meet inclusion criteria.

Brief summary: The purpose of this study is to compare work of breathing on different levels of high flow respiratory support on infants born between 27 and 37 weeks gestation.


Eligibility criteria: Inclusion Criteria:

* Infants between 27 and 37 weeks corrected gestational age
* \>4 days PNA
* Stable (i.e. not meeting exclusion criteria) and receiving non-invasive respiratory support (HFNC) for ≥ 12 hours
* Requiring ≤ 40% supplemental FiO2 as determined by the clinical care team for clinical care purposes independent of this study

Exclusion Criteria:

* Infants with skeletal, neuromuscular, or abdominal surgical disorders that affect the accuracy of WOB measurements

Primary outcomes:
measure: Work of breathing indices
timeFrame: 2 hours
Secondary outcomes:
measure: Intermittent hypoxia
timeFrame: 2 hours
Other outcomes:
Locations:
city: Newark
country: United States
facility: Christiana Care Health Services, Inc.
state: Delaware
Study officials:
affiliation: Christiana Care Health Services, Inc.
name: Kelley Kovatis, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00229294: Fibromyalgia in Men Suffering From PTSD
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fibromyalgia
Posttraumatic Stress Disorder
Major Depressive Disorder
Lead sponsor: Sheba Medical Center
Sponsor class: OTHER_GOV
First posted: 2005-09-29
Sex: MALE
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Time perspective: RETROSPECTIVE

Brief summary: Assessing FM and psychiatric state among PTSD, MDD and healthy participants


Eligibility criteria: Inclusion Criteria:

* Healthy volunteers without any current or past psychiatric disorder
* Current diagnosis of PTSD
* Current diagnosis of MDD

Exclusion Criteria:

- Psychotic features

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Tel Aviv University
name: Joseph Zohar, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03229694: the Effect of Tracleer on Tourniquet-associated Hypertension
Official title: Effect of Endothelin Receptor Blocker Tracleer on Toruniquet-associated Hypertension During Total Knee Arthroplasty
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Tourniquets
Hypertension
Bosentan
Lead sponsor: Xuzhou Medical University
Sponsor class: OTHER
First posted: 2017-07-25
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Tourniquet is widely used in orthopedic surgery. However, prolonged tourniquet inflation may cause a gradual rise in blood pressure, which named as tourniquet-associated hypertension. Thus, to effectively prevent the tourniquet related hemodynamic responses is important for patients receiving limb surgery.

Tracleer is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension. Tracleer can also be used to treat retistant hypertension. At present trial, the investigators are going to investigate the effect of Tracleer on tourniquet-associated hypertension during total knee arthroplasty.

Detailed description: At present study, the investigators will use endothelin receptor antagonist, Tracleer (Bosentan), to investigate the effect of Tracleer on tourniquet-associated hypertension during unilateral total knee arthroplasty, and evaluate its safety and effectivity. The purpose of this study is to find a new therapy to prevent and treat tourniquet-associated hypertension.

Eligibility criteria: Inclusion Criteria:

* Patients underwent selected total knee arthroplasty under general anesthesia
* ASA II-III
* 18\~65 years old
* Signed informed consent voluntarily

Exclusion Criteria:

* Do not apply tourniquet during the surgery
* Patients underwent emergency surgery
* Having applied tourniquet in last three months
* Patients underwent bilateral total knee arthroplasty
* Dysfunction of liver or kidney
* Anemia (Hb \<90 g/L)
* Serious myocardial disease (eg. coronary heart disease, heart failure, severe arrhythmia)
* Coagulation disorder
* Diabetic
* Leukocyte higher than normal value
* Pneumonia, asthma, chronic obstructive pulmonary disease
* Hypotension before surgery (systolic pressure \< 90 mmHg)
* Pregnant woman or puerpera
* Having being enrolled in other clinical trial in last 3 months

Primary outcomes:
measure: Maximum rate of change in systolic blood pressure (MR)
timeFrame: 24 hours after surgery
Secondary outcomes:
measure: the concentration of endothelin-1, 5-hydroxytrypatamine, and norepinephrine
timeFrame: baseline and intraoperative
measure: visual analog scale
timeFrame: 24 hrs after surgery
Other outcomes:
Locations:
city: Xuzhou
country: China
facility: The Affiliated Hospital of Xuzhou Medical University
state: Jiangsu
Study officials:
affiliation: The Affiliated Hospital of Xuzhou Medical University
name: Su Liu, doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02415894: Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy in Ukraine
Official title: Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Ukraine
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Other Abortion
Lead sponsor: Gynuity Health Projects
Sponsor class: OTHER
First posted: 2015-04-14
Enrollment: 172
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Women with mid-trimester pregnancy seeking abortion

Brief summary: The goal of this study is to examine the effectiveness and feasibility of a mifepristone-misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Ukraine.


Eligibility criteria: Inclusion Criteria:

* Having an ongoing pregnancy of 13-22 weeks gestation
* Be willing to undergo surgical completion if necessary
* Have no contraindications to study procedures, according to provider
* Be willing and able to consent to participate in the study
* Be willing to follow study procedures

Exclusion Criteria:

* Known allergy to mifepristone or misoprostol/prostaglandin
* Any contraindications to vaginal delivery, including placenta previa
* Unable to provide consent

Primary outcomes:
measure: Rate of successful abortion
timeFrame: 15 hours after start of misoprostol induction
Secondary outcomes:
Other outcomes:
Locations:
city: Odessa
country: Ukraine
facility: Odessa Regional Hospital
city: Poltava
country: Ukraine
facility: Poltava City Maternity Hospital
city: Vinnitsa
country: Ukraine
facility: Vinnitsa Regional Hospital
Study officials:
affiliation: Gynuity Health Projects
name: Tamar Tsereteli, MD, PhD
role: STUDY_DIRECTOR
affiliation: Woman Health and Family Planning Charitable Foundation
name: Galina Maistruk, MD
role: STUDY_DIRECTOR
References:
citation: Platais I, Tsereteli T, Maystruk G, Kurbanbekova D, Winikoff B. A prospective study of mifepristone and unlimited dosing of sublingual misoprostol for termination of second-trimester pregnancy in Uzbekistan and Ukraine. BMJ Sex Reprod Health. 2019 Jun 4:bmjsrh-2018-200167. doi: 10.1136/bmjsrh-2018-200167. Online ahead of print.
Clinical trial NCT04872894: Familial Hypocalciuric Hypercalcemia: Clinical Aspects and Evolution
Official title: Familial Hypocalciuric Hypercalcemia: Clinical Aspects and Evolution
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Familial Hypocalciuric Hypercalcemia
Keywords: hypercalcemia
Familial Benign Hypercalcemia
Familial hypocalciuric hypercalcemia
Lead sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Sponsor class: OTHER
Collaborators: name: Hospital Clinic of Barcelona
First posted: 2021-05-05
Enrollment: 70
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with biochemical and clinical suspicion of FHH, namely hypercalcemia, hypophospatemia, normal or elevated parathormone levels and very low urine calcium excretion defined as a calcium creatinine clearance ratio \<0.01, and who were asked at discretion of the clinician for a genetic evaluation of any of the FHH causing genes.

Brief summary: Familial hypocalciuric hypercalcemia (FHH) is a rare disease (ORPHA#405, www.orpha.net) and most likely underdiagnosed, that clinicians should be aware of in the differential diagnosis of a hypercalcemia. Appropriate identification of the FHH has implications in treatment and also for the family, since it is an automosal-dominant disease, due to mostly a heterozygous loss-of-function mutation of the CASR (calcium-sensing receptor) gene, but also much less freqüent mutations of another two genes (AP2S1 and GNA11). In case of clinical and biochemical suspicion of FHH, a genetic evaluation is mandatory. Nevertheless, an important number of patients, the genetic study is negative. This observational study is intended to perform a descriptive review of cases with clinical and biochemical suspicion of FHH who underwent a genetic study in the usual clinical practice. Clinical, biochemical and radiological characteristics, treatment, follow-up and comorbidities of genotype-negative participants will be compared with genotype-positive cases.


Eligibility criteria: Inclusion Criteria:

* Patients with clinical and biochemical suspicion of FHH who, at the discretion of the physician in routine clinical practice, were asked to perform a genetic evaluation of FHH and whose genetic results are available.

Exclusion Criteria:

* Genetic study of FHH is not available or was not performed despite clinical and biochemical suspicion of FHH.

Primary outcomes:
measure: Age (years)
timeFrame: 1 year
measure: Gender distribution (%)
timeFrame: 1 year
measure: Calcium levels (mg/dL)
timeFrame: Through study completion, an average of 1 year
measure: Parathyroid Ultrasound results
timeFrame: 1 year
Secondary outcomes:
measure: Treatment modalities used
timeFrame: 1 year
measure: FHH associated comorbidities
timeFrame: Through study completion, an average of 1 year
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital de la Santa Creu i Sant Pau
Study officials:
References: